Objective Real-World Outcomes of Patients Suffering from Painful Neurogenic Claudication Treated with the *mild*[®] Procedure: Interim 6-Month Report of a Randomized Controlled Trial

Timothy Deer¹
Christopher Kim¹
Sayed Emal Wahezi²
Huaguang Qu³
Dawood Sayed⁴

On Behalf of The MOTION
Study Investigators

¹The Spine & Nerve Centers of the Virginias, Charleston, WV, USA;
²Montefiore Health System, Bronx, NY, USA; ³Pennsylvania Pain & Spine Institute, Chalfont, PA, USA; ⁴The University of Kansas Medical Center, Kansas City, KS, USA

Background: Lumbar spinal stenosis (LSS) is a serious degenerative condition of the spine that can cause significant functional disability. Therapies for these patients generally begin with conservative management, since more invasive interventions such as open surgery and spinal implants are associated with higher complication rates. Early in the treatment algorithm for LSS patients, multiple conventional medical management (CMM) therapies are often combined as an initial low-risk treatment strategy. This composite first-line treatment plan may include conservative care together with early interventional treatment options such as epidural steroid injections, radiofrequency ablation and the *mild*[®] Procedure.

Methods: This prospective randomized controlled trial evaluates patients aged 50 to 80 years treated with *mild* plus CMM, compared to those treated with CMM alone, as the active control. Walking tolerance test outcomes and incidence of subsequent disallowed procedures provided objective real-world outcome data. The incidence of device or procedure-related adverse events was analyzed. Follow-up includes 6-month, 1-year and 2-year assessments, with 1-year being primary. Patients in the *mild*+CMM group are followed at 3, 4, and 5 years. This is a report of interim 6-month outcomes.

Results: Of 155 patients enrolled at 19 US interventional pain management centers, 78 were allocated to CMM-Alone, and 77 to *mild*+CMM. At 6-months, the validated walking tolerance test demonstrated statistical superiority of *mild*+CMM versus CMM-Alone ($p<0.001$). The incidence of patients receiving a subsequent disallowed procedure, and thereby considered treatment failures in their study group, was statistically significantly higher in CMM-Alone versus *mild*+CMM ($p<0.001$). There were no device or procedure-related adverse events in either group.

Conclusion: At 6-months, the *mild* Procedure combined with CMM provided statistically superior objective real-world outcomes versus CMM-Alone. There were no device or procedure-related adverse events reported in either study group. With its excellent safety profile and superior efficacy, *mild* is uniquely positioned as early first-line therapy.

Keywords: *mild*[®], minimally invasive lumbar decompression, lumbar spinal stenosis, neurogenic claudication, ligamentum flavum

Correspondence: Timothy Deer
The Spine & Nerve Centers of the Virginias, 400 Court Street, Suite 100, Charleston, WV, 25301, USA
Tel +1 304 347 6120
Fax +1 304 347 6126
Email doctdeer@aol.com

Introduction

Lumbar spinal stenosis (LSS), a serious degenerative condition of the spine, is associated with significant functional disability and chronic pain. LSS is caused by structural narrowing of the spinal canal and resulting ischemic compression of

neural elements leading to symptomatic neurogenic claudication. Intervertebral disc degeneration, hypertrophic ligamentum flavum (HLF), and bony pathology are consistently present in patients with neurogenic claudication.^{1,2} This range of pathologies can lead to central canal stenosis as well as foraminal and lateral recess stenosis. HLF is a major cause of neurogenic claudication for LSS patients, and contributes up to 85% of spinal canal narrowing.³ LSS patients suffering from neurogenic claudication commonly present with multiple types of stenosis and numerous spinal comorbidities.⁴ Therapies for these patients generally begin with conservative management, since more invasive interventions such as interspinous spacers, surgical decompression and spinal fusion are associated with higher complication rates.⁴⁻⁷ Early in the treatment algorithm for LSS patients, multiple conventional medical management (CMM) therapies are often combined as an initial low-risk treatment strategy. This composite first-line treatment plan may include physical therapy, home exercise programs, and pain medication, together with early interventional procedures such as epidural steroid injections, radiofrequency ablation and the *mild*[®] Procedure (Vertos Medical, Aliso Viejo, CA, USA).

The MOTION study is a prospective, multicenter, randomized controlled trial (RCT) evaluating functional improvement in LSS patients aged 50–80 years with neurogenic claudication who are treated with the *mild* Procedure plus CMM (*mild*+CMM), compared to those treated with CMM alone (CMM-Alone), as the active control. Patients in the control group are able to crossover and receive *mild* after completion of 1-year follow-up and prior to 2-years. The goal of the MOTION study is to provide Level 1 evidence of the safety and effectiveness of *mild*+CMM versus CMM-Alone in managing neurogenic claudication symptoms in patients with verified HLF as a contributing factor. Validated functional improvement measures provide objective outcome data for patients treated with the *mild* Procedure as first-line therapy in a real-world setting that does not restrict the use of adjunctive conventional medical management measures in either study group. The MOTION study is registered with the US Clinical Trial Registry (NCT03610737). Interim 6-month objective real-world outcomes for patients enrolled in this study are reported.

Patients and Methods

Nineteen interventional pain management centers in the United States are participating in the MOTION study,

providing real-world data from academic medical centers, community hospitals and ambulatory surgical centers (ASCs) (See [Appendix](#)). All investigators have undergone training on the *mild* Procedure and are experienced users of *mild* instrumentation. Institutional Review Board approval was obtained for all sites and Consolidated Standards of Reporting Trials (CONSORT) guidelines were followed.⁸ All patients provided written informed consent to participate in this study, and the study is being conducted in accordance with the Declaration of Helsinki.

Primary inclusion and exclusion criteria, as well as study symptomatic diagnosis screening requirements to confirm symptoms of neurogenic claudication,⁹ are presented in [Table 1](#). Patients with comorbid conditions commonly associated with spinal stenosis, such as osteophytes, facet hypertrophy, minor spondylolisthesis (Grade I without instability), foraminal stenosis, and/or disc protrusion were included unless the condition was deemed to be too advanced. The study Medical Monitor reviewed the medical records of all potential patients to confirm eligibility and approve for enrollment. Patients were 50 to 80 years of age, with evidence of ligamentum flavum $\geq 2.5\text{mm}$ ¹⁰ confirmed by preoperative imaging.

Patients were randomly assigned in equal number (1:1) to the *mild*+CMM treatment arm or CMM-Alone as the active control. Patient allocation to study arm was accomplished by the site using an interactive electronic data capture (EDC) system. Prior to randomization, each patient's inclusion/exclusion criteria data points were entered into the EDC system. Once the patient was determined to be eligible for the study based on the selection criteria responses provided, the EDC system automatically generated the assigned treatment group.

Patients in both study groups are required to complete 6-month, 1-year and 2-year follow-up assessments, with 1-year being the primary endpoint of the study. Further, patients in the *mild*+CMM group, together with those in the CMM-Alone group that crossover to receive *mild* prior to 2-year follow-up, will be followed at 3, 4, and 5 years.

Interventions

The *mild* Procedure

The *mild* Procedure is used to treat LSS patients suffering from neurogenic claudication by selectively removing small portions of lamina and HLF, and thereby relieving pressure on nerve roots. *mild* devices are designed to percutaneously access the interlaminar space through a 5.1mm port positioned in the patient's posterior lumbar

Table I Selection Criteria and Neurogenic Claudication Symptomatic Diagnosis

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> • Age: 50–80 years • Patients experiencing neurogenic claudication symptoms for at least 3 months duration. LSS with neurogenic claudication diagnosed via: <ol style="list-style-type: none"> a. Symptomatic diagnosis⁹ (see below). and <ol style="list-style-type: none"> b. Radiologic evidence of LSS with ligamentum flavum ≥ 2.5mm in thickness¹⁰ confirmed by pre-op MRI or CT performed within 12 months of baseline visit. • Stable opioid intake with no change during 30 days prior to enrollment. • Available to complete all follow-up visits. 	<ul style="list-style-type: none"> • Oswestry Disability Index (ODI) score <31 (0–100 ODI Scale). • Numeric Pain Rating Scale (NPRS) score <5 (0–10 NPRS Scale). • Lumbar epidural steroid injections during 8 weeks prior to study enrollment. • Baseline analgesic medication greater than >90 mg morphine equivalent (MME) per day. • Prior surgery, interspinous spacer, intradiscal procedure, vertebral augmentation, or <i>mild</i> Procedure at the same treatment level. • Radiofrequency ablation at the same or the adjacent levels within 6 months prior to study enrollment. • History of spinal fractures with current related pain symptoms. • Grade II or higher spondylolisthesis. • Motor deficit or disabling back and/or leg pain from causes other than LSS neurogenic claudication. • Unable to walk ≥ 10 feet unaided before being limited by pain. • Previously randomized and/or treated in a similar clinical study. • Epidural lipomatosis (if deemed to be a significant contributor of canal narrowing).
Neurogenic Claudication Symptomatic Diagnosis	
<ol style="list-style-type: none"> 1) Pain/Discomfort in leg, buttocks, or lower back while walking or standing. 2) Bending forward or sitting down provides relief. 3) Bending forward while walking. 4) Unable to stand unaided without bending at the waist for more than 15 minutes. 5) Unable to walk unaided without bending at the waist for more than one-quarter mile. 	

spine. Generally, only moderate sedation and local anesthetic are required, and the small access port minimizes trauma to tissue and bony structures of the spine. *mild* treatment can be performed unilaterally or bilaterally, and at multiple levels. *mild* leaves no implants behind, and patients typically resume normal activity within 24 hours with no restrictions.^{4,7,11} The *mild* Procedure has been previously described.⁷ All study *mild* Procedures were conducted in accordance with the product labeling and indications for use.

Conventional Medical Management

Conventional Medical Management involves treatment with one or more conservative or interventional therapies that are commonly used for early treatment of LSS with neurogenic claudication. The study investigators at each site determine what CMM is optimal for each patient. CMM therapies may include physical therapy, home exercise programs, pain medication, epidural steroid injections (ESIs), nerve blocks, facet joint injections, medial branch injections, trigger point injections, sacroiliac joint injections, radiofrequency ablation and other conservative therapies such as back brace, walking aid, and chiropractic care. All CMM therapies performed are documented and reported throughout the course of the study.

Outcome Measures

Clinical outcome measures for this interim report focus on objective measurements of function and pain. These objective outcome measures included the validated walking tolerance test described by Deen et al,¹² which is designed to define baseline functional status and response to treatment at follow-up. During this test, patients walk upright on a flat surface for up to 15 minutes at their preferred speed. The examination is stopped after 15 minutes or at onset of severe symptoms. In this study, the walking tolerance test is administered to all patients at baseline and at all follow-ups.

Another important outcome measure of the MOTION study protocol is the rate of subsequent disallowed procedures which is used as a proxy for study treatment failure. Patients receiving a disallowed procedure to treat continuing symptoms of neurogenic claudication are deemed to be non-responders in their treatment group and are considered study failures. This objective outcome measure is reported and compared as an incidence rate of patients receiving subsequent disallowed procedures in each study group. Lumbar therapies that are disallowed in this study include adhesiolysis, kyphoplasty, neurostimulator, interspinous spacers, and spine surgery. *mild* Procedures are disallowed for patients in the CMM-Alone study arm.

Figure 1 Study patient flow through 6-month follow-up.

For all outcome measures, statistical superiority is tested for *mild+CMM* versus CMM-Alone, as the active control. Safety is reported as the incidence of device/procedure-related adverse events, as adjudicated by an independent clinical event adjudicator. All serious adverse events regardless of relationship are also reported. All subjective clinical outcomes, including the composite primary endpoint, will be reported at 1-year to minimize bias.

Sample Size and Power

Sample size was calculated to obtain at least 90% power for testing the primary superiority hypothesis. The total sample size of 155 is sufficient to meet this objective under the assumption of a 2-sided hypothesis, type 1 error of 0.05, power $(1-\beta)$ at least 90%, randomization ratio of 1:1, and accounting for dropouts.

Statistical Methods

Descriptive summaries are presented by randomized group for all baseline and outcome measures. Continuous data is summarized using means and standard deviations, while categorical variables are summarized using frequency counts and percentages. For events that can occur more than once in a single subject (eg, adverse events), the

percentage is based on subjects experiencing the event, and both patient and event counts are reported. All p-values presented are two-sided using the Fisher Exact Probability Test, with values less than 0.05 considered statistically significant.

Results Patients

A total of 181 patients signed study informed consent for study evaluation, and of those, 26 were excluded because they did not meet the study selection criteria. The remaining 155 patients were enrolled in the MOTION study from September 2018 through December 2019. Randomization placed 78 patients in the CMM-Alone group and 77 in *mild+CMM*. The number of patients in each study group was balanced within investigational sites. Following randomization, two CMM-Alone and five *mild+CMM* patients were not treated, and four CMM-Alone patients voluntarily withdrew for unrelated reasons. Of the remaining patients, two CMM-Alone and one *mild+CMM* missed their 6-month follow-up visit, resulting in 70 CMM-Alone and 71 *mild+CMM* patients. Figure 1 presents the participant flow through 6 months.

Table 2 Patient Demographics and Presenting Spinal Comorbidities

Characteristic	CMM-Alone N=78	mild+CMM N=77	p-value
Age (Years) ^a	66.8 ± 7.5	64.7 ± 7.1	0.077
Gender			
Male	42.1% (33)	42.9% (33)	1.000
Female	57.7% (45)	57.1% (44)	
Presenting Spinal Comorbidities			
Ligamentum flavum hypertrophy	100.0% (78)	100.0% (77)	1.000
Foraminal narrowing	93.6% (73)	92.2% (71)	0.765
Bulging disc	94.9% (74)	89.6% (69)	0.246
Facet arthropathy	75.6% (59)	72.7% (56)	0.716
Facet hypertrophy	75.6% (59)	67.5% (52)	0.289
Degenerative disc disease	53.9% (42)	63.6% (49)	0.254
Lateral recess narrowing	53.9% (42)	57.1% (44)	0.747
Disc space loss	47.4% (37)	57.1% (44)	0.262
Nerve root impingement	43.6% (34)	41.6% (32)	0.871
Spondylosis	35.9% (28)	45.5% (35)	0.254
Osteophytes	41.0% (32)	37.7% (29)	0.743
Spondylolisthesis	32.1% (25)	32.5% (25)	1.000
Herniated disc	21.8% (17)	26.0% (20)	0.576
Scoliosis	7.7% (6)	5.2% (4)	0.746
Other	20.5% (16)	16.9% (13)	0.681

Note: ^aMean ± SD.

Abbreviation: SD, standard deviation.

Gender distribution was similar between groups, and while the difference did not reach statistical significance, patients in the CMM-Alone group were on average 2 years

older than patients in the *mild*+CMM group (CMM-Alone: 66.8 years, *mild*+CMM: 64.7 years, $p=0.077$). Overall, 91% of the patients presented with five or more spinal

Figure 2 Distribution of MOTION patients presenting with multiple types of stenosis and spinal comorbidities. Over 50% of the patients presented with all three types of stenosis—central, lateral and foraminal. Further, less than 5% had central stenosis only. Over 90% of the patients presented with 5 or more spinal comorbidities, and nearly 20% presented with over 10 spinal comorbidities.

comorbidities. The most common lumbar spine comorbidities in addition to HLF were foraminal narrowing, bulging disc, facet arthropathy and facet hypertrophy. All presenting spinal comorbidities occurred at a similar rate between groups. There were no significant baseline differences between the groups. (See Table 2.) It is important to note that MOTION patients also presented with multiple types of stenosis. While 100% of the patients had central stenosis, 93% and 55% also suffered from foraminal stenosis and lateral stenosis, respectively. Only 5% of the patients had central stenosis alone. Figure 2 presents the categorical frequencies of multiple types of stenosis and spinal comorbidities for MOTION patients at baseline presentation.

Procedures

mild Procedure data for the *mild*+CMM group is provided in Table 3. Approximately two-thirds of *mild* cases were conducted in the hospital outpatient setting, with one-third performed in an ASC. The most common lumbar level treated with *mild* was L4-L5 (76.4%), followed by L3-L4 (52.8%), L2-L3 (13.9%), and L5-S1 (5.6%). Over 90% of the patients were treated bilaterally, and 59.7% were treated at one level,

31.9% at two levels, and the remaining 8.3% at three levels. The majority of *mild* patients (93%) underwent monitored anesthesia care (MAC) sedation, moderate sedation, and/or local anesthesia, with the balance receiving a combination of general/local anesthesia. All *mild* patients were discharged within 24 hours of the procedure.

Per the study protocol, patients in both treatment arms were able to receive conventional medical management therapies. These CMM therapies included conservative treatments such as physical therapy, home exercise programs, and walking aids, and specified interventional treatments which included ESIs, nerve blocks, other steroid injections, and radiofrequency ablation. Overall, the only difference between the study groups in the incidence of CMM treatments received during 6-month follow-up is facet injections which were significantly higher in the CMM-Alone group (8/70 in CMM-Alone versus 1/71 in *mild*+CMM, $p=0.017$). The number of patients receiving CMM conservative and interventional therapies is presented in Table 4.

Functional Efficacy Outcomes

With a specific focus on objective measurement of function, the walking tolerance test revealed a marked difference between the two study groups. The number of *mild* +CMM patients able to walk the full 15 minutes increased more than three-fold from baseline to 6 months, while the number of CMM-Alone patients decreased by one patient over the same period. This difference at 6 months demonstrated statistical superiority of the *mild*+CMM group versus CMM-Alone ($p<0.001$). (See Figure 3.) During 6-month follow-up, 17 patients (24.3%) in the CMM-Alone group and two patients (2.8%) in the *mild* +CMM group received a subsequent disallowed procedure (Figure 4). The incidence of patients receiving a subsequent disallowed procedure, and thereby considered treatment failures in their study group, was statistically significantly higher in the CMM-Alone group versus the *mild*+CMM group ($p<0.001$). Table 5 presents the specific disallowed therapies received by patients in both study groups.

Safety

There were no device or procedure-related adverse events in either group, and the incidence of all serious, non-related adverse events was not statistically significantly different between groups (5.1% and 3.9% for CMM-Alone and *mild*+CMM, respectively) ($p=1.000$).

Table 3 *mild* Procedure Information

Metric	<i>mild</i> +CMM N=72
Procedure setting, % (N)	
ASC	34.7 (25)
Hospital outpatient	65.3 (47)
Anesthesia type, % (N)	
MAC sedation only	79.2 (57)
Moderate sedation	9.7 (7)
Local and MAC	4.2 (3)
General only	2.8 (2)
Local only	2.8 (2)
General and local	1.4 (1)
Levels treated, % (N)	
L2-L3	13.9 (10)
L3-L4	52.8 (38)
L4-L5	76.4 (55)
L5-S1	5.6 (4)
Unilateral treatment, % (N)	9.7 (7)
Bilateral treatment, % (N)	90.3 (65)
Number of levels treated, % (N)	
1	59.7 (43)
2	31.9 (23)
3	8.3 (6)

Abbreviations: ASC, ambulatory surgery centers; MAC, monitored anesthesia care.

Table 4 CMM Therapy Received by Patients in Both Study Groups Through 6-Month Follow-Up

Treatment	CMM-Alone N=70	mild+CMM N=71	p-value
Total – received therapies	70.0% (49)	70.4% (50)	1.000
Multiple therapies	37.1% (26)	33.8% (24)	0.727
Conservative Therapy			
Home exercise	21.8% (17)	26.0% (20)	0.703
Walking aid	14.1% (11)	26.0% (20)	0.103
Physical therapy	23.1% (18)	18.2% (14)	0.427
Tens	3.8% (3)	6.5% (5)	0.719
Chiropractic	3.8% (3)	5.2% (4)	1.000
Back brace	5.1% (4)	5.2% (4)	1.000
Acupuncture	2.6% (2)	5.2% (4)	0.681
Aqua therapy	5.1% (2)	2.6% (2)	1.000
Activity restriction	0.0% (0)	2.6% (2)	0.497
Bed rest	0.0% (0)	1.3% (1)	1.000
Other therapy (inversion table, heat, massage, wellness center)	1.3% (1)	5.2% (4)	0.366
Interventional Therapy			
Lumbar epidural steroid injections	44.3% (31)	29.6% (21)	0.082
Single ESI	26	17	
Two ESI	4	3	
Three ESI	1	1	
Sacroiliac joint injection	7.1% (5)	5.6% (4)	0.745
Medial branch injection	10.0% (7)	5.6% (4)	0.366
Radiofrequency ablation	1.4% (1)	2.8% (2)	1.000
Facet injection	11.4% (8)	1.4% (1)	0.017 ^a
Trigger point injection	4.3% (3)	0.0% (0)	0.120
Other therapy (GTB injection, hip/knee injections, PRP)	1.4% (1)	8.5% (6)	0.116

Note: ^aSignificant difference between groups.

Abbreviations: ESI, epidural steroid injection; GTB, greater trochanteric bursa; PRP, platelet-rich plasma.

Discussion

The MOTION study was designed to provide objective functional improvement data for patients treated with the *mild* Procedure as first-line therapy in a real-world setting. In this study, centers were chosen to reflect real-world practice, and CMM is allowed in both study arms at the full discretion of the investigators, which is standard of care. Therefore, study patients are treated exactly as they would be outside of the study. The only difference between study groups is that the *mild* Procedure is disallowed in the CMM-Alone arm and it is allowed in the *mild* +CMM arm. Results from this RCT provide Level 1 evidence of the difference in patient outcomes for patients able to receive *mild*, versus those who are not able to receive *mild*, in a setting where all other CMM treatment options are allowed.

The MOTION study relies on multiple validated outcome measures, with a focus on analyzing and reporting

objective outcome data. The strength of objective outcomes is that they are independent of judgement and are therefore less susceptible to bias.^{12–16} At 6-month follow-up, two objective outcome measures demonstrated statistically significant superiority of *mild*+CMM versus CMM-Alone. First, the walking tolerance test resulting in an over three-fold increase in *mild*+CMM patients able to walk for the full 15 minutes of the test, versus a decrease for CMM-Alone patients. By the 6-month follow-up time point, half of the *mild*+CMM patients were able to walk the full 15 minutes versus only 13% of the patients in the CMM-Alone arm. The ability to walk further without severe symptoms provides a valuable quality of life improvement for these patients. Second, the use of subsequent disallowed procedures as a proxy for study treatment failure provides a second objective outcome measure that is widely accepted and often used in the real-world analysis of Medicare Claims

Figure 3 Walking tolerance test results at baseline and 6-month follow-up. Comparison of the number of patients able to walk 15 minutes without experiencing severe neurogenic claudication symptoms at baseline versus 6-month follow-up for both study groups.

Figure 4 Patients receiving disallowed therapy during 6-month follow-up. In this study, disallowed procedures are used as a proxy for study group treatment failure.

Data.⁶ The incidence rate of patients receiving subsequent disallowed procedures is over eight times higher in the CMM-Alone group (24.3%) compared to *mild*+CMM (2.8%). This pronounced difference is

remarkable and demonstrates a distinctly different treatment path between the two study groups.

Patients in this study presented with multiple comorbidities and multiple types of stenosis. Nearly all patients (91%) suffered from five or more spinal comorbidities, and over 50% presented with all three types of stenosis—central, lateral and foraminal (Figure 2). In addition to ligamentum flavum thickening, other spinal comorbidities may contribute to spinal narrowing including intervertebral disc degeneration and bone overgrowth. While the spinal degenerative cascade is complex and introduces numerous potential spinal comorbidities and areas of stenosis, debulking the ligamentum flavum with *mild* has successfully treated LSS narrowing due to multiple etiologies in the clinical setting. Similar to the MOTION study, the large majority of patients in the ENCORE RCT presented with foraminal stenosis, bulging disc or facet hypertrophy, and these comorbid conditions were determined to be positive predictors of success with *mild*.^{4,11}

Mekhail et al studied functional improvements in Standing Time and Walking Distance following treatment with the *mild* Procedure. At 1-year follow-up, 40 patients in this study experienced a mean seven-fold increase in Standing Time and 16-fold increase in Walking Distance.

Table 5 Disallowed Therapies Received by Each Study Group Through 6-Month Follow-Up

Disallowed Therapy	CMM-Alone N=70	mild+CMM N=71
Total (p<0.001) ^a	24.3% (17)	2.8% (2)
<i>mild</i> Procedure	12.9% (9)	–
Lumbar surgery—type unknown	5.7% (4)	–
Laminectomy	1.4% (1)	–
Laminectomy and spacer	–	1.4% (1)
Lumbar decompression	–	1.4% (1)
Lumbar fusion	1.4% (1)	–
Spacer	1.4% (1)	–
Stimulator	1.4% (1)	–

Note: ^aSignificant difference between groups.

These objective outcome measures directly evaluated patient quality of recovery and provided a real-world report of statistically significant functional improvement for these patients.¹⁷

There were no device or procedure-related adverse events reported for either arm in the MOTION study. This level of safety for the *mild* Procedure is supported by 13 clinical studies, including 2 Level 1 RCTs, that have demonstrated statistically significant efficacy improvement, superiority of *mild* versus ESIs, and low complication rates.^{4,7,18–20} In fact, the safety of *mild* has been shown to be similar to ESIs at a 1.3% rate of device or procedure-related complications for both study groups in the ENCORE RCT.¹⁹ It is important to note that all conservative and interventional therapies included in CMM in the MOTION study are positioned early in the treatment algorithm due to their low risk (Table 4). With its excellent safety profile and superior efficacy, *mild* is uniquely positioned as early first-line therapy.

In the event these first-line CMM therapies do not provide adequate relief for symptoms of neurogenic claudication, LSS patients may choose to undergo more invasive treatments such as interspinous spacers, laminectomy, and spinal fusion that are associated with higher complication rates. These refractory patients represent a significantly different patient profile than those early in the continuum of care.^{4,7} While the clinical superiority of *mild* to ESIs/CMM has been established by this and two other RCTs,^{19,20} a suggested comparison of *mild* to open surgery presents several methodological challenges. First, these patient populations are at completely different phases on the treatment algorithm. Early patients are seeking to

delay or avoid surgery altogether.²¹ Further, the considerable difference in invasiveness would lead to difficulty with enrollment and post randomization withdrawals due to patients opting out to receive their desired therapy. Due to these fundamental barriers, a valid RCT of this comparison is not feasible. Almost one-third of the US population is covered for reimbursement of the *mild* Procedure. This includes all Medicare carriers, the Veterans Administration, and multiple commercial plans. It is also covered by Walmart's Centers of Excellence program for the treatment of LSS.

Limitations of this study include the lack of blinding which was not possible due to the use of an active comparator that allows for a broad range of both conservative and interventional treatments in both study groups. It is anticipated that patients in both arms may continue to receive CMM therapies throughout the study period. The real-world nature of this study, which allows the use of CMM in both study arms at the full discretion of the investigator, is also a limitation due to use of various standard of care treatment algorithms. All CMM treatments as well as subsequent disallowed procedures are recorded. Patients who receive a disallowed procedure remain in the study and are assessed at all follow-ups.

Conclusion

Six-month results of this RCT demonstrate that the *mild* Procedure combined with CMM provides statistically superior objective real-world outcomes versus CMM-Alone for LSS patients with neurogenic claudication and verified ligamentum flavum hypertrophy. There were no device or procedure-related adverse events reported in either MOTION study group. This strong overall level of safety supports the positioning of these conservative and interventional therapies early in the treatment algorithm due to their established low risk. With its excellent safety profile and superior efficacy, *mild* is uniquely positioned as early first-line therapy.

Data Sharing Statement

The datasets related to the current study are available from the corresponding author.

Ethics Approval and Informed Consent

Institutional Review Board approval was obtained for all sites. All patients provided written informed consent to

participate in this study, and the study is being conducted in accordance with the Declaration of Helsinki.

Acknowledgment

The authors wish to thank Dennis Gilman, PhD, of ClinDM for statistical analysis.

Author Contributions

All authors made significant contributions to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation of data, or in all of these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study is sponsored by Vertos Medical. The sponsorship includes study-related supplies and expenses, as well as funding for statistical analysis services by an independent provider.

Disclosure

Timothy Deer is the research principal investigator on this study and is a consultant for Abbott, Axonics, Ethos, Flowonix, Mainstay, SpineThera, SPR Therapeutic, SI Bone, Nevro, Saluda, CornerLoc, PainTEQ, Nalu, Boston Scientific (Vertiflex), Vertos, and Medtronic (Stimgenics). He has received research funding from Abbott, Boston Scientific, Vertos, and Avanos. Christopher Kim is a consultant for Boston Scientific (Vertiflex), Vertos, PainTEQ, and Abbott. Sayed Emal Wahezi is a consultant for Boston Scientific and a research investigator for Abbott. Huaguang Qu is a consultant for Boston Scientific, Vertos, and Flowonix. Dawood Sayed is a consultant for Abbott, Medtronic, Nevro, SPR, Vertos, and PainTEQ, and has received research funding and holds minority equity in Vertos. The authors report no other conflicts of interest in this work.

References

- Katz JN, Harris MB. Lumbar spinal stenosis. *N Engl J Med*. 2008;358(8):818–825. doi:10.1056/NEJMcp0708097
- Porter RW. Spinal stenosis and neurogenic claudication. *Spine*. 1996;21(17):2046–2052. doi:10.1097/00007632-199609010-00024
- Hansson T, Suzuki N, Hebelka H, Gaulitz A. The narrowing of the lumbar spinal canal during loaded MRI: the effects of the disc and ligamentum flavum. *Eur Spine J*. 2009;18:679–686. doi:10.1007/s00586-009-0919-7
- Staats PS, Chafin TB, Golovac S, et al. Long-term safety and efficacy of minimally invasive lumbar decompression procedure for the treatment of lumbar spinal stenosis with neurogenic claudication: 2-year results of MiDAS ENCORE. *Reg Anesth Pain Med*. 2018;43:789–794. doi:10.1097/AAP.0000000000000868
- Weinstein JN, Tosteson RD, Lurie JD, et al. Surgical versus nonsurgical therapy for lumbar spinal stenosis. *N Engl J Med*. 2008;358:794–810. doi:10.1056/NEJMoa0707136
- Deyo RA, Martin BI, Ching A, et al. Interspinous spacers compared with decompression or fusion for lumbar stenosis: complications and repeat operations in the Medicare population. *Spine*. 2013;38(10):865–872. doi:10.1097/BRS.0b013e31828631b8
- Jain S, Deer TR, Sayed D, et al. Minimally invasive lumbar decompression: a review of indications, techniques, efficacy and safety. *Pain Manag*. 2020;10:331–348. doi:10.2217/pmt-2020-0037
- Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. *BMJ*. 2010;340:c869. doi:10.1136/bmj.c869
- Sandella DE, Haig AJ, Tomkins-Lane C, Yamakawa K. Defining the clinical syndrome of lumbar spinal stenosis: a recursive specialist survey process. *PMR*. 2013;5(6):491–495. doi:10.1016/j.pmrj.2012.10.001
- Park JB, Chang H, Lee JK. Quantitative analysis of transforming growth factor-beta 1 in ligamentum flavum of lumbar spinal stenosis and disc herniation. *Spine*. 2001;26:E492–E495. doi:10.1097/00007632-200111010-00007
- Deer TR, Grider JS, Pope JE, et al. The MIST guidelines: the Lumbar Spinal Stenosis Consensus Group guidelines for minimally invasive spine treatment. *Pain Pract*. 2019;19(3):250–274. doi:10.1111/papr.12744
- Deen HG, Zimmerman RS, Lyons MK, McPhee MC, Verheijde JL, Lemens SM. Measurement of exercise tolerance on the treadmill in patients with symptomatic lumbar spinal stenosis: a useful indicator of functional status and surgical outcome. *J Neurosurg*. 1995;83(1):27–30. doi:10.3171/jns.1995.83.1.0027
- Bowyer A, Royse C. A matter of perspective – objective versus subjective outcomes in the assessment of quality of recovery. *Best Pract Res Clin Anaesthesiol*. 2018;32(3–4):287–294. doi:10.1016/j.bpa.2018.02.003
- Page MJ, Higgins JPT, Clayton G, Sterne JAC, Hróbjartsson A, Savović J. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. *PLoS One*. 2016;11:e0159267. doi:10.1371/journal.pone.0159267
- Moustgaard H, Bello S, Miller FG, Hróbjartsson A. Subjective and objective outcomes in randomized clinical trials: definitions differed in methods publications and were often absent from trial reports. *J Clin Epidemiol*. 2014;67(12):1327–1334. doi:10.1016/j.jclinepi.2014.06.020
- Savovic J, Jones HE, Altman DG, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, control trials. *Ann Intern Med*. 2012;156:429–438. doi:10.7326/0003-4819-157-6-201209180-00537
- Mekhail N, Costandi S, Abraham B, Samuel SW. Functional and patient-reported outcomes in symptomatic lumbar spinal stenosis following percutaneous decompression. *Pain Pract*. 2012;12(6):417–425. doi:10.1111/j.1533-2500.2012.00565.x
- Staats PS, Benyamin RM. MiDAS ENCORE: randomized controlled clinical trial report of 6-month results. *Pain Physician*. 2016;19:25–37. doi:10.36076/ppj/2016.19.25
- Benyamin RM, Staats PS. *mild®* is an effective treatment for lumbar spinal stenosis with neurogenic claudication: miDAS ENCORE Randomized Controlled Trial. *Pain Physician*. 2016;19:229–242. doi:10.36076/ppj/2019.19.229

20. Brown L. A double-blind, randomized, prospective study of epidural steroid injection vs. the *mild*[®] procedure in patients with symptomatic lumbar spinal stenosis. *Pain Pract.* 2012;12(5):333–341. doi:10.1111/j.1533-2500.2011.00518.x
21. Mekhail NA, Costandi SJ, Armanyous S, et al. The impact of age on the outcomes of minimally invasive lumbar decompression for lumbar spinal stenosis. *Med Devices.* 2020;13:151–161. doi:10.2147/MDER.S251556

Journal of Pain Research

Dovepress

Publish your work in this journal

The Journal of Pain Research is an international, peer reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication. The manuscript

management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-pain-research-journal>